Axiom Advisory’s Alnylam Pharmaceuticals ALNY Stock Holding History

Axiom Advisory’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	$283K	Buy	+1,088	New	+$283K	﹤0.01%	259

Other funds holding ALNY

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Axiom Advisory's ALNY Position: Q3 2024 in Review

Axiom Advisory opened a new position in Alnylam Pharmaceuticals (ALNY) in Q3 2024: 1,088 shares worth $283K. The stake represents ﹤0.01% of the portfolio and ranks #259 among its holdings.

566 funds tracked by Wall St. Rank hold ALNY as of Q3 2024.

Axiom Advisory held 1,088 shares of Alnylam Pharmaceuticals worth $283K as of Q3 2024.
Alnylam Pharmaceuticals was a new Axiom Advisory position in Q3 2024.
Alnylam Pharmaceuticals made up ﹤0.01% of Axiom Advisory's portfolio in Q3 2024, its #259 holding.
566 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2024.

Based on Axiom Advisory's 13F filing for Q3 2024, filed 7 Oct 2024.